Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by CEL-SCI Corporation < Previous 1 2 Next > CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results May 12, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock April 27, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer April 19, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension March 08, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology March 03, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results February 15, 2023 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments December 28, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Issues Letter to Shareholders November 22, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment October 17, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer September 12, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Issues Letter to Shareholders September 07, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov August 19, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results August 15, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors August 08, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Announces Reddit AMA with Geert Kersten July 14, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation to Present at LD Micro Invitational June 08, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO June 07, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Publication of ASCO 2022 Abstracts May 27, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results May 16, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces Acceptance of Abstracts to ASCO 2022 April 22, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results February 14, 2022 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments December 22, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility October 22, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results August 16, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Issues Letter to Shareholders July 07, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available July 02, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021 June 30, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study June 28, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting June 25, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering June 11, 2021 From CEL-SCI Corporation Via Business Wire Tickers CVM < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.